Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon (OGN)
NYSE:OGN
Holding OGN?
Track your performance easily
OGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.84 - $23.10
Previous Close$19.97
Volume2.65M
Average Volume (3M)1.65M
Market Cap
$5.14B
Enterprise Value$13.09B
Total Cash (Recent Filing)$704.00M
Total Debt (Recent Filing)$8.66B
Price to Earnings (P/E)5.3
Beta1.09
Next Earnings
Oct 31, 2024Last Dividend Ex-Date
Aug 16, 2024Dividend Yield5.45%
Share Statistics
EPS (TTM)3.89
Shares Outstanding257,473,477
10 Day Avg. Volume1,545,768
30 Day Avg. Volume1,654,191
Standard Deviation0.13
R-Squared0.12
Alpha-0.00322
Financial Highlights & Ratios
Price to Book (P/B)35.66
Price to Sales (P/S)0.83
Price to Cash Flow (P/CF)4.00
P/FCF Ratio3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda15.10
Forecast
1Y Price Target
$21.00Price Target Upside4.06% Upside
Rating ConsensusHold
Number of Analyst Covering6
Organon News
Bulls Say, Bears Say
Bulls Say
Capital ManagementManagement continues to characterize their approach to capital allocation as 'prudent', with servicing of the dividend (unchanged) as a top priority, along with debt pay down, then consideration of business development opportunities to expand the portfolio.
DiversificationOGN is diversifying into a US branded area (immunology/dermatology) outside of where they have a meaningful presence.
Market PotentialThe deal is seen as a positive for OGN given that both psoriasis and atopic dermatitis represent sizeable branded markets.
Bears Say
Debt LevelsOGN expects net leverage to be elevated above 4x as a result of the deal.
Financial PerformanceThe transaction is expected to be moderately dilutive to adjusted EBITDA in 2025.
Market PositionThe established brands business has stabilized but we see gradual erosion of the franchise over time.
---
Ownership Overview
0.21% Insiders
34.63% Mutual Funds
46.82% Other Institutional Investors
18.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon’s price range in the past 12 months?
Organon lowest stock price was $10.84 and its highest was $23.10 in the past 12 months.
What is Organon’s market cap?
Currently, no data Available
When is Organon’s upcoming earnings report date?
Organon’s upcoming earnings report date is Oct 31, 2024 which is in 40 days.
How were Organon’s earnings last quarter?
Organon released its earnings results on Aug 06, 2024. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.076 by $0.044.
Is Organon overvalued?
According to Wall Street analysts Organon’s price is currently Undervalued.
Does Organon pay dividends?
Organon pays a Quarterly dividend of $0.28 which represents an annual dividend yield of 5.45%. See more information on Organon dividends here
What is Organon’s EPS estimate?
Organon’s EPS estimate is $1.
How many shares outstanding does Organon have?
Organon has 257,473,480 shares outstanding.
What happened to Organon’s price movement after its last earnings report?
Organon reported an EPS of $1.12 in its last earnings report, beating expectations of $1.076. Following the earnings report the stock price went down -7.634%.
Which hedge fund is a major shareholder of Organon?
Among the largest hedge funds holding Organon’s share is Slate Path Capital LP. It holds Organon’s shares valued at 112M.
---
Organon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.00 (4.06% Upside)
$21.00 (4.06% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 127.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.70%
Trailing 12-Months
Company Description
Organon
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q2 2024
0:00 / 0:00
---
OGN Stock 12 Month Forecast
Average Price Target
$21.00
▲(4.06% Upside)
Technical Analysis
Baxter International
―
Teva Pharmaceutical
―
Perrigo Company
―
Amphastar Pharmaceuticals
―
Best Analysts Covering OGN
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+20.44%
assigned a buy rating 2 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.44% per trade.
---